TMCI · CIK 1630627
What Treace Medical Concepts, Inc. told the SEC could break it.
Treace's disclosures track the dependencies of a focused medical-device maker. Demand for its bunion-correction systems rests on regulation and reimbursement on both ends: all of its existing products are cleared through the FDA's 510(k) pathway and subject to pervasive post-market oversight, and sales hinge on hospitals, surgery centers, and surgeons being reimbursed by private insurers, Medicare, and Medicaid. Its balance sheet adds a $175M senior secured SLR loan that gives the lender liens over substantially all of its assets, including intellectual property, on default, and its operations are concentrated in a single Ponte Vedra, Florida headquarters — also where it assembles part of its sterile kits — in a hurricane-exposed location.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- FDA medical-device regulation (510(k) pathway)medium
All of Treace's existing products are FDA-cleared via the 510(k) pathway and subject to pervasive post-market regulation; future products may require costlier IDE/PMA routes.
“We are not currently undertaking any FDA IDE trials, as all of our existing products are FDA-cleared through the 510(k) pathway.”
SEC filing →As of 2026 - third-party payor coverage & reimbursement for bunion procedureslow
Demand for Treace's systems depends on hospitals, ASCs and surgeons being reimbursed by private insurers, Medicare and Medicaid; adverse coverage or reimbursement decisions would directly cut product sales.
“Hospitals, ambulatory surgery centers and surgeons that purchase or use our products generally rely on third-party payors to reimburse for all or part of the costs and fees associated with procedures using our products.”
SEC filing →As of 2026
Liquidity & debt
- SLR senior secured loan; liens on substantially all assets incl. IPmedium
Treace's December 2025 $175M senior secured SLR loan grants the lender liens over substantially all assets, including intellectual property, exercisable on default — and accelerated debt could exceed available cash.
“SLR would have the right to enforce liens and security interests in substantially all of our assets (including intellectual property) in the event of certain specified defaults under the loans with SLR.”
SEC filing →As of 2026
Geographic concentration
- single corporate HQ / sterile-kit assembly in Ponte Vedra, Floridalow
Treace operates from a single ~125,000 sq ft headquarters in Ponte Vedra, Florida, where it also assembles a portion of its sterile kits — concentrating operations in one hurricane-exposed site.
“As of December 31, 2025, we leased approximately 125,000 square feet for our corporate headquarters located in Ponte Vedra, Florida under a lease agreement which terminates in July 2032.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch